SABCS 2022 Conference Coverage

 

Videos
09:01

SABCS 2022 Conference Coverage

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study

FEATURING Wassim Mchayleh
  • 304 views
  • February 7, 2023
  • 1
11:09

SABCS 2022 Conference Coverage

SABCS 2022 Results From a Pre-Planned monarchE OS Interim Analysis, Including 4-Year Efficacy Outcomes: Abemaciclib + ET for HR+/HER2-/N+ High-Risk EBC

FEATURING Jens Huober
  • 284 views
  • January 30, 2023
  • 1
22:22

SABCS 2022 Conference Coverage

SABCS 2022 Genomic Analysis of ctDNA From Patients With HR+, HER2-Mutant mBC Enrolled in SUMMIT: Mechanisms of Acquired Resistance to Neratinib + Fulvestrant + Trastuzumab

FEATURING Cynthia Ma
  • 86 views
  • January 30, 2023
06:10

SABCS 2022 Conference Coverage

SABCS 2022: The Effect of Race on Pathologic Complete Response Rates and Overall Survival in Patients With TNBC

FEATURING Hannah Woriax
  • 26 views
  • January 25, 2023
12:44

SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the Randomized Phase II RIGHT Choice Trial: Premenopausal Patients With Aggressive HR+/HER2- Advanced BC Treated With Ribociclib + ET vs. Physician’s Choice Combination Chemo

FEATURING Yen-Shen Lu
  • 212 views
  • January 20, 2023
06:42

SABCS 2022 Conference Coverage

SABCS 2022 Long-Term Survival of the GeparOLA Study: Neoadjuvant Paclitaxel/Olaparib vs. Paclitaxel/Carboplatinum in Patients With HER2- BC and Homologous Recombination Deficiency

FEATURING Peter Fasching
  • 102 views
  • January 20, 2023
27:50

SABCS 2022 Conference Coverage

SABCS 2022 Beyond Anthracyclines and Trastuzumab: Cardiotoxicity of New Novel Agents

FEATURING Susan Dent
  • 72 views
  • January 16, 2023
  • 1
10:47

SABCS 2022 Conference Coverage

SABCS 2022 Population-Based Estimates of Contralateral BC Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1/2, CHEK2, and PALB2

FEATURING Siddhartha Yadav
  • 123 views
  • January 9, 2023
  • 1
04:21

SABCS 2022 Conference Coverage

SABCS 2022 on the OPHELIA Study: Olaparib + Trastuzumab in HER2+ BRCAm Advanced Breast Cancer Patients

FEATURING José Martínez
  • 193 views
  • January 5, 2023
  • 2
11:09

SABCS 2022 Conference Coverage

SABCS 2022 Primary Results of the Randomized Phase 3 DESTINY-Breast02 Study: T-DXd vs. Physician’s Choice in HER2+ Unresectable and/or mBC Previously Treated With Trastuzumab Emtansine

FEATURING Ian Krop
  • 154 views
  • January 5, 2023
  • 1
07:32

SABCS 2022 Conference Coverage

SABCS 2022 Early TNBC Treated With Neoadjuvant Chemo: Association of PCR and Breast-Conserving Surgery With Improved Prognosis

FEATURING David Krug
  • 220 views
  • January 5, 2023
  • 4
15:23

SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the POSITIVE Trial (IBCSG 48-14 / BIG 8-13): Pregnancy Outcome & Safety of Interrupting Therapy for Women With Endocrine Responsive BC

FEATURING Hatem Azim
  • 193 views
  • January 2, 2023
  • 3
08:39

SABCS 2022 Conference Coverage

SABCS 2022 Tumor-Agnostic Measurement of ctDNA Levels With mFAST-SeqS in 1L HR+/HER2- mBC

FEATURING Noortje Verschoor
  • 254 views
  • December 24, 2022
  • 3
07:39

SABCS 2022 Conference Coverage

SABCS 2022 Post-Neoadjuvant Therapy in TNBC: To Clip or Not to Clip

FEATURING Viviana Galimberti
  • 154 views
  • December 24, 2022
13:46

SABCS 2022 Conference Coverage

SABCS 2022 TROPiCS-02 Phase 3 Study of Patients With HR+/HER2- mBC: Sacituzumab Govitecan vs. Treatment of Physician’s Choice - Efficacy by Trop-2 Expression

FEATURING Hope Rugo
  • 172 views
  • December 23, 2022
  • 3
07:41

SABCS 2022 Conference Coverage

SABCS 2022 DETECT V Phase 3 Trial: Omission of Chemo in the Treatment of HER2+ & HR+ mBC

FEATURING Wolfgang Janni
  • 786 views
  • December 23, 2022
  • 4
07:15

SABCS 2022 Conference Coverage

SABCS 2022: CBD Oil - A Potential Solution in Case of Severe Tamoxifen-Related Side Effects in BC

FEATURING Sanne Buijs
  • 331 views
  • December 23, 2022
  • 4
05:38

SABCS 2022 Conference Coverage

SABCS 2022: Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and 21-Gene Oncotype DX Recurrence Score

FEATURING Rima Patel
  • 483 views
  • December 23, 2022
  • 5
02:16

SABCS 2022 Conference Coverage

SABCS 2022 Phase 2 Expansion (VERITAC) of a Phase 1/2 Study: ARV-471, a PROTAC® ER Degrader in Advanced ER+/HER2- BC

FEATURING Erika Hamilton
  • 146 views
  • December 22, 2022
  • 1
10:47

SABCS 2022 Conference Coverage

SABCS 2022 Dose-Expansion Study DESTINY-Breast07: T-DXd as Monotherapy or Combined With Pertuzumab in Patients With Metastatic HER2+ BC

FEATURING Erika Hamilton
  • 174 views
  • December 22, 2022
19:54

SABCS 2022 Conference Coverage

SABCS 2022 Hormonal Exposures and Cancer Risk in BRCA1/2 Mutation Carriers

FEATURING Joanne Kotsopoulos
  • 312 views
  • December 20, 2022
  • 3
05:34

SABCS 2022 Conference Coverage

SABCS 2022 Identifying Drivers of 1L HR+/HER2- mBC Treatment Choices

FEATURING Adam Brufsky
  • 437 views
  • December 20, 2022
  • 2
06:45

SABCS 2022 Conference Coverage

SABCS 2022 Post Hoc Analysis of Adjuvant RT in the Phase 3 KEYNOTE-522 Study: Neoadjuvant Pembro + Chemo vs. Placebo + Chemo Followed by Adjuvant Pembro vs. Placebo for Early TNBC

FEATURING Heather McArthur
  • 271 views
  • December 20, 2022
  • 2
13:17

SABCS 2022 Conference Coverage

SABCS 2022 Post Neoadjuvant Therapy in TNBC

FEATURING Heather McArthur
  • 491 views
  • December 20, 2022
  • 3
07:30

SABCS 2022 Conference Coverage

SABCS 2022 Impact of Adjuvant ET Omission in ER+ BC Treated With Neoadjuvant Chemo

FEATURING Grace Choong
  • 24 views
  • December 20, 2022
12:42

SABCS 2022 Conference Coverage

SABCS 2022 Multicenter Retrospective ROSET-BM Study: T-DXd for the Treatment of Patients With HER2+ BC With Brain and/or Leptomeningeal Metastases

FEATURING Yamanaka Takashi
  • 102 views
  • December 19, 2022
  • 1
05:36

SABCS 2022 Conference Coverage

SABCS 2022 Breast Preservation After Local Recurrence of BC: Comparison of Length and QoL Between Breast Conserving Surgery With Intraoperative RT (TARGIT-IORT) vs. Mastectomy

FEATURING Hans-Christian Kolberg
  • 94 views
  • December 19, 2022
04:44

SABCS 2022 Conference Coverage

SABCS 2022 Molecular Fluorescence-Guided Surgery Using BEVA800 for the Assessment of Tumor Margins During Breast Conserving Surgery of Patients With Primary BC (MARGIN-II)

FEATURING Hans-Christian Kolberg
  • 25 views
  • December 19, 2022
07:24

SABCS 2022 Conference Coverage

SABCS 2022 Comparison of a Mono Atezo Window Followed by Atezo & Chemo vs. Atezo and Chemo Alone in TNBC: Interim Analysis of the Adaptive Randomized Neoadjuvant Trial neoMono

FEATURING Hans-Christian Kolberg
  • 80 views
  • December 19, 2022
19:57

SABCS 2022 Conference Coverage

SABCS 2022 Challenging Types of Breast Cancer: Lobular/Pleomorphic

FEATURING Sibylle Loibl
  • 262 views
  • December 19, 2022
05:50

SABCS 2022 Conference Coverage

SABCS 2022 PENELOPE-B and PALLAS Trials: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early BC

FEATURING Sibylle Loibl
  • 365 views
  • December 19, 2022
05:45

SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC: Final 10-Year Results and HER2DX Analysis

FEATURING Sara Tolaney
  • 1,887 views
  • December 19, 2022
  • 10
02:31

SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rates of Adverse Events of Sacituzumab Govitecan vs. Treatment of Physician’s Choice in HR+/HER2- mBC

FEATURING Sara Tolaney
  • 74 views
  • December 19, 2022
  • 1
12:21

SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 Randomized Controlled Trial: Addition of Platinum to Sequential Taxane-Anthracycline Neoadjuvant Chemo in TNBC

FEATURING Sudeep Gupta
  • 130 views
  • December 19, 2022
  • 2
10:25

SABCS 2022 Conference Coverage

SABCS 2022 Biology and Clinical Course of Lobular Cancer in BC

FEATURING Rachel Layman
  • 564 views
  • December 19, 2022
  • 3
06:48

SABCS 2022 Conference Coverage

SABCS 2022: PgR Levels & Ki67 Expression of Lobular Carcinomas of the Breast Might Indicate OncotypeDX Testing to Evaluate Chemotherapy Benefit

FEATURING Christos Markopoulos
  • 165 views
  • December 19, 2022
  • 4
10:52

SABCS 2022 Conference Coverage

SABCS 2022 Patient-Reported Cognitive Impairment in Women Participating in the RxPONDER Trial (SWOG S1007) by Menopausal Status

FEATURING Irene Kang
  • 69 views
  • December 19, 2022
16:23

SABCS 2022 Conference Coverage

SABCS 2022 Immune Landscape and Microenvironments in BC

FEATURING Michail Ignatiadis
  • 64 views
  • December 16, 2022
  • 1
16:49

SABCS 2022 Conference Coverage

SABCS 2022 Inflammatory Breast Cancer: A Perfect Storm

FEATURING Filipa Lynce
  • 306 views
  • December 16, 2022
  • 3
06:37

SABCS 2022 Conference Coverage

SABCS 2022 High PD-L2 Protein Expression in Cancer Cells Is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors

FEATURING Lubna Chaudhary
  • 227 views
  • December 16, 2022
  • 2
10:17

SABCS 2022 Conference Coverage

SABCS 2022 Clinical Use of Breast Cancer Index for Prediction of Late BC Recurrence and Prediction of Benefit in Extended ET: A Single Institution Experience

FEATURING Vrushali Dabak
  • 258 views
  • December 16, 2022
  • 2
20:32

SABCS 2022 Conference Coverage

SABCS 2022: Enhancing the Effects of Immunotherapy in Metastatic Breast Cancer

FEATURING Margaret Gatti-Mays
  • 295 views
  • December 16, 2022
  • 2
07:48

SABCS 2022 Conference Coverage

SABCS 2022: Real-World 2L Treatment Patterns and Associated Clinical Outcomes for 2795 Patients With Advanced HR+/HER2- BC Treated With 1L CDK4/6i

FEATURING Katherine Clifton
  • 267 views
  • December 16, 2022
  • 1
04:32

SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TAILORx Breast Cancer Trial: 21-Gene Recurrence Score and OS

FEATURING Sherry Yang
  • 856 views
  • December 16, 2022
  • 3
11:42

SABCS 2022 Conference Coverage

SABCS 2022: Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+ BC

FEATURING Laura Kennedy
  • 86 views
  • December 16, 2022
12:00

SABCS 2022 Conference Coverage

SABCS 2022 CDK4/6 Inhibitors: Are They All the Same or Different?

FEATURING Debra Patt
  • 860 views
  • December 15, 2022
  • 5
10:01

SABCS 2022 Conference Coverage

SABCS 2022 Results of the Randomized, Multi-Dose Phase 2 SERENA-2 Trial: Camizestrant, a Next-Gen Oral SERD vs. Fulvestrant in Post-Menopausal Women With Advanced ER+/HER2- BC

FEATURING Mafalda Oliveira
  • 237 views
  • December 15, 2022
  • 1
10:10

SABCS 2022 Conference Coverage

SABCS 2022 Results from ACOSOG Z11102 (Alliance): Impact of Breast Conservation Therapy on Local Recurrence in Patients With Multiple Ipsilateral Breast Cancer

FEATURING Judy Boughey
  • 90 views
  • December 15, 2022
  • 1
14:58

SABCS 2022 Conference Coverage

SABCS 2022 Poster Reviews of Special Populations: Male Breast Cancer

FEATURING Jose Pablo Leone
  • 243 views
  • December 15, 2022
  • 1
09:13

SABCS 2022 Conference Coverage

SABCS 2022 Predictors of Response to Neoadjuvant Chemo in Breast Cancer: OncotypeDX vs. MammaPrint vs. Liquid Biopsy

FEATURING Nadeem Bilani
  • 531 views
  • December 15, 2022
  • 4
13:17

SABCS 2022 Conference Coverage

SABCS 2022 Chemotherapy-Induced Cardio Toxicity: The Patient Experience

FEATURING Alexea Gaffney-Adams
  • 57 views
  • December 15, 2022
12:02

SABCS 2022 Conference Coverage

SABCS 2022 10-Year Results of a Phase 3 Trial of Low-Dose Tamoxifen in Non-Invasive Breast Cancer

FEATURING Andrea De Censi
  • 1,497 views
  • December 15, 2022
  • 3
14:28

SABCS 2022 Conference Coverage

SABCS 2022 EMERALD Phase 3 Trial Updated Results by Duration of Prior CDK4/6i: Elacestrant vs. SoC ET in Patients With ER+/HER2- mBC

FEATURING Hung Khong
  • 1,633 views
  • December 14, 2022
  • 11
18:43

SABCS 2022 Conference Coverage

SABCS 2022 Antibody Drug Conjugates for TNBC

FEATURING Leif Ellisen
  • 146 views
  • December 14, 2022
  • 1
13:05

SABCS 2022 Conference Coverage

SABCS 2022 Stromal Tumor-Infiltrating Lymphocytes Identify Early-Stage TNBC Patients With Favorable Outcomes at 10-Year Follow-Up in the Absence of Systemic Therapy: A Pooled Analysis of 1835 Patients

FEATURING Roberto Leon Ferre
  • 75 views
  • December 14, 2022
  • 1
12:54

SABCS 2022 Conference Coverage

SABCS 2022 Phase III SWOG S1207 Trial: Evaluating Adjuvant ET +/- 1 Year of Everolimus in Patients With High-Risk HR+/HER2- BC

FEATURING Mariana Chavez Mac Gregor
  • 62 views
  • December 14, 2022
  • 1
09:40

SABCS 2022 Conference Coverage

SABCS 2022 Updated Survival Results of the Randomized Phase 3 Study DESTINY-Breast03: T-DXd vs. Trastuzumab Emtansine in Patients With HER2+ mBC

FEATURING Sara A. Hurvitz
  • 259 views
  • December 14, 2022
08:25

SABCS 2022 Conference Coverage

SABCS 2022 Race & Clinical Outcomes in the RxPONDER Trial (SWOG S1007): A Clinical Trial Rx for Positive Node, Endocrine Responsive BC

FEATURING Yara Abdou
  • 64 views
  • December 14, 2022
  • 1
05:53

SABCS 2022 Conference Coverage

SABCS 2022 Patient-Reported Outcomes From the TROPiCS-02 Trial: The Effect of Sacituzumab Govitecan vs. Chemotherapy in HR+/HER2- mBC

FEATURING Frederik Marmé
  • 63 views
  • December 13, 2022
25:01

SABCS 2022 Conference Coverage

SABCS 2022: FLASH-RT, Ultra-High Dose Rate Rate Radiotherapy, Is as Effective as Conventional Dose Rate Radiotherapy in Eradicating Tumor in a Preclinical Model of Breast Cancer

FEATURING Frederick Dirbas
  • 222 views
  • December 13, 2022
04:35

SABCS 2022 Conference Coverage

SABCS 2022 5-Year Results and Correlative Analyses From ATEMPT (TBCRC033): Adjuvant Trastuzumab Emtansine vs. Paclitaxel + Trastuzumab for Stage I HER2+ BC

FEATURING Paolo Tarantino
  • 278 views
  • December 13, 2022
03:14

SABCS 2022 Conference Coverage

SABCS 2022: Comprehensive Genomic Characterization of HER2-Low Breast Cancer

FEATURING Paolo Tarantino
  • 355 views
  • December 13, 2022
  • 1
06:54

SABCS 2022 Conference Coverage

SABCS 2022 Correlative Analysis From NeoPACT and NeoSTOP Trials: Association of TNBC-DX Scores With Outcomes in TNBC Treated With Neoadjuvant Pembro and Chemo

FEATURING Priyanka Sharma
  • 134 views
  • December 13, 2022
06:51

SABCS 2022 Conference Coverage

SABCS 2022: Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer

FEATURING Rani Bansal
  • 92 views
  • December 13, 2022
10:46

SABCS 2022 Conference Coverage

SABCS 2022 on a Randomized Phase II PACE (Palbociclib After CDK4/6i & ET) Study: Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-Treated ER+/HER2- mBC

FEATURING Erica Mayer
  • 333 views
  • December 13, 2022
  • 5
49:07

SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

FEATURING Joyce O'Shaughnessy, Sara Tolaney, Sara A. Hurvitz, Hope Rugo
  • 5,944 views
  • December 13, 2022
  • 36
08:33

SABCS 2022 Conference Coverage

SABCS 2022 Validation of Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) in a Meta-Analysis of Three Randomized Controlled Trials of Breast Conserving Surgery +/- Radiotherapy

FEATURING Per Karlsson
  • 89 views
  • December 12, 2022
  • 1
03:02

SABCS 2022 Conference Coverage

SABCS 2022 Clinical and Molecular Characteristics of HER2-Low/Zero Early Stage Triple-Negative Breast Cancer

FEATURING Clinton Yam
  • 390 views
  • December 12, 2022
  • 1
08:15

SABCS 2022 Conference Coverage

SABCS 2022 Absence of Lobular Carcinoma in Situ, a Poor Prognostic Marker in Invasive Lobular Carcinoma

FEATURING Jason Mouabbi
  • 283 views
  • December 12, 2022
  • 2